Sven Golfier
Berlin, BE, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer.
Journal: Cancer discovery
Published: May 14, 2025
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
Journal: Cell chemical biology
Published: September 18, 2023
T cell-mediated elimination of cancer cells by blocking CEACAM6-CEACAM1 interaction.
Journal: Oncoimmunology
Published: February 10, 2022
Characterization of BAY 1905254, an Immune Checkpoint Inhibitor Targeting the Immunoglobulin-Like Domain Containing Receptor 2 (ILDR2).
Journal: Cancer immunology research
Published: May 08, 2019
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Journal: Molecular cancer therapeutics
Published: January 14, 2019
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 24, 2018
Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Journal: Oncotarget
Published: January 19, 2018
Preclinical Antitumor Efficacy of BAY 1129980-a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody-Drug Conjugate for the Treatment of Non-Small Cell Lung Cancer.
Journal: Molecular cancer therapeutics
Published: July 20, 2016
Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors.
Journal: Clinical cancer drugs
Published: November 27, 2015
Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Journal: Molecular cancer therapeutics
Published: April 10, 2014
3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions.
Journal: Experimental cell research
Published: November 11, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026